Ari M. Melnick

The Flt3 internal tandem duplication mutant inhibits the function of transcriptional repressors by blocking interactions with SMRT.

The theoretical basis of transcriptional therapy of cancer: can it be put into practice?

Derepression in the desert: the third workshop on clinical translation of epigenetics in cancer therapeutics.

BCL6 is critical for the development of a diverse primary B cell repertoire.

EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis.

Epigenetics in AML.

BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia.

SYK inhibition and response prediction in diffuse large B-cell lymphoma.

The Bcl6-SMRT/NCoR cistrome represses inflammation to attenuate atherosclerosis.

Oncogene-mediated alterations in chromatin conformation.

Genome-wide detection of genes targeted by non-Ig somatic hypermutation in lymphoma.

Negative regulation of osteoclast precursor differentiation by CD11b and β2 integrin-B-cell lymphoma 6 signaling.

Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms.

Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia.

Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression.

Notch activation inhibits AML growth and survival: a potential therapeutic approach.

BCL6 breaks occur at different AID sequence motifs in Ig-BCL6 and non-Ig-BCL6 rearrangements.

EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.

New effector functions and regulatory mechanisms of BCL6 in normal and malignant lymphocytes.

Differentiation therapy for IDH1/2 mutant malignancies.

Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia.

Hematopoietic Stem Cell Origin of BRAFV600E Mutations in Hairy Cell Leukemia.

Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.

Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas.

The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia.